Deerfield Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Deerfield Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-496,291	Closed	-$5.28M	–	106
2019 Q1	$5.28M	Sell	496,291 -753,709	-60%	-$7.51M	0.2%	71
2018 Q4	$9.96M	Buy	+1,250,000	New	+$18M	0.4%	60
2017 Q4	–	Sell	-131,500	Closed	-$7.24M	–	108
2017 Q3	$7.24M	Buy	131,500 +101,602	+340%	+$17.1M	0.33%	71
2017 Q2	$5.55M	Sell	29,898 -41,103	-58%	-$7.2M	0.3%	66
2017 Q1	$8.49M	Hold	71,001	–	–	0.33%	75
2016 Q4	$7.05M	Hold	71,001	–	–	0.29%	69
2016 Q3	$7.95M	Buy	+71,001	New	+$8.52M	0.37%	52
2015 Q4	–	Sell	-60,583	Closed	-$6.26M	–	132
2015 Q3	$6.26M	Buy	+60,583	New	+$7.1M	0.24%	82

Other funds holding SIOX

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Deerfield Management's SIOX Position: Q2 2019 in Review

Deerfield Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2019, closing a stake of 496,291 shares — an estimated $5.28M sold.

Deerfield Management first reported a position in SIOX in Q3 2015 and held it in 8 quarters. The position peaked at $9.96M in Q4 2018. 39 funds tracked by Wall St. Rank hold SIOX as of Q2 2019.

Deerfield Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Deerfield Management sold 496,291 Sio Gene Therapies Inc. Common Stock shares in Q2 2019, an estimated $5.28M.
Deerfield Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 8 quarters.
Deerfield Management's Sio Gene Therapies Inc. Common Stock position peaked at $9.96M in Q4 2018.
39 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2019.

Based on Deerfield Management's 13F filing for Q2 2019, filed 14 Aug 2019.